Moderna surprises the Street by predicting a bigger-than-expected sales drop
Shares of Moderna tumbled Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year ...
Moderna cuts 2025 sales forecast by $1 bln on weak vaccine demand, shares tumble
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...
Moderna May Have The Best Shot At A Vaccine For Stomach Flu
Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.
AI could solve greatest human challenges, if we let it, Moderna cofounder says
Combining human efforts, nature, and AI in what Noubar Afeyan calls “polyintelligence” could solve problems such as climate ...
Why Moderna Stock Just Crashed 21%
Moderna 's ( MRNA -20.49%) sales are slowing down, and Moderna stock is going down -- a lot. The coronavirus vaccine maker's ...
FiercePharma1d
JPM25: Moderna slashes guidance, plots $1B in cost cuts this year amid lackluster vaccine sales
Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...
Moderna 2025 Revenue Guidance Below Wall Street’s Estimates
The biotech company said it expects between $1.5 billion and $2.5 billion in revenue this year, below Wall Street ...
Monthly Prescribing Reference22h
Moderna Provides Update on Norovirus Vaccine Candidate
Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial investigating a ...